301 related articles for article (PubMed ID: 30605054)
1. Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations.
Elena C; Chiara M; Angelica B; Chiara MA; Laura N; Chiara C; Claudio C; Antonella F; Nicola G
Curr Pharm Biotechnol; 2018; 19(15):1210-1220. PubMed ID: 30605054
[TBL] [Abstract][Full Text] [Related]
2. [Diagnosis and therapy of steroid-induced hyperglycemia based on literature reports].
Dąbrowski P; Majdan M
Wiad Lek; 2016; 69(4):642-645. PubMed ID: 27941203
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the Treatment of Steroid-Induced Hyperglycemia.
Wallace MD; Metzger NL
Ann Pharmacother; 2018 Jan; 52(1):86-90. PubMed ID: 28836444
[TBL] [Abstract][Full Text] [Related]
4. Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy.
Rowbottom L; Stinson J; McDonald R; Emmenegger U; Cheng S; Lowe J; Giotis A; Cheon P; Chow R; Pasetka M; Thavarajah N; Pulenzas N; Chow E; DeAngelis C
Ann Palliat Med; 2015 Apr; 4(2):70-7. PubMed ID: 25971294
[TBL] [Abstract][Full Text] [Related]
5. Anti-Hyperglycemic Agents for the Treatment of Type 2 Diabetes Mellitus: Role in Cardioprotection During the Last Decade.
Kocyigit D; Gurses KM; Yalcin MU; Tokgozoglu L
Endocr Metab Immune Disord Drug Targets; 2017; 17(1):19-31. PubMed ID: 28440199
[TBL] [Abstract][Full Text] [Related]
6. The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring.
Yata Y; Hosojima M; Kabasawa H; Ishikawa T; Kaseda R; Iino N; Suzuki Y; Saito A; Narita I
Intern Med; 2017 Oct; 56(19):2555-2562. PubMed ID: 28883231
[TBL] [Abstract][Full Text] [Related]
7. Newly approved and promising antidiabetic agents.
Combettes M; Kargar C
Therapie; 2007; 62(4):293-310. PubMed ID: 17983555
[TBL] [Abstract][Full Text] [Related]
8. Drug selection and the management of corticosteroid-related diabetes mellitus.
Hoogwerf B; Danese RD
Rheum Dis Clin North Am; 1999 Aug; 25(3):489-505. PubMed ID: 10467625
[TBL] [Abstract][Full Text] [Related]
9. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
10. Drugs and hyperglycemia: A practical guide.
Jain V; Patel RK; Kapadia Z; Galiveeti S; Banerji M; Hope L
Maturitas; 2017 Oct; 104():80-83. PubMed ID: 28923179
[TBL] [Abstract][Full Text] [Related]
11. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
[TBL] [Abstract][Full Text] [Related]
12. [Steroid-induced hyperglycemia, a common clinical problem in medicine without evidence-based guidelines].
Genolet P; Petite C; Petignat PA
Rev Med Suisse; 2012 Apr; 8(336):800-2, 804-5. PubMed ID: 22574414
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trial of the efficacy and safety of insulin glargine vs. NPH insulin as basal insulin for the treatment of glucocorticoid induced hyperglycemia using continuous glucose monitoring in hospitalized patients with type 2 diabetes and respiratory disease.
Ruiz de Adana MS; Colomo N; Maldonado-Araque C; Fontalba MI; Linares F; García-Torres F; Fernández R; Bautista C; Olveira G; de la Cruz JL; Rojo-Martínez G; Valdés S
Diabetes Res Clin Pract; 2015 Nov; 110(2):158-65. PubMed ID: 26474657
[TBL] [Abstract][Full Text] [Related]
14. Glycemic/metabolic responses to identical meal tolerance tests at breakfast, lunch and dinner in Japanese patients with type 2 diabetes mellitus treated with a dipeptidyl peptidase-4 inhibitor and the effects of adding a mitiglinide/voglibose fixed-dose combination.
Ono Y; Kamoshima H; Nakamura A; Nomoto H
Expert Opin Pharmacother; 2014 Sep; 15(13):1785-95. PubMed ID: 25046055
[TBL] [Abstract][Full Text] [Related]
15. Impact of Current and Emerging Glucose-Lowering Drugs on Body Weight in Type 2 Diabetes.
Lau DC; Teoh H
Can J Diabetes; 2015 Dec; 39 Suppl 5():S148-54. PubMed ID: 26654858
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus.
Hussain S; Chowdhury TA
Drugs; 2019 Feb; 79(3):231-242. PubMed ID: 30742277
[TBL] [Abstract][Full Text] [Related]
17. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
Baretić M; Troskot R
Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
[TBL] [Abstract][Full Text] [Related]
18. Glucocorticoid-induced hyperglycemia and diabetes: Practical points.
Descours M; Rigalleau V
Ann Endocrinol (Paris); 2023 May; 84(3):353-356. PubMed ID: 36967046
[TBL] [Abstract][Full Text] [Related]
19. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
[TBL] [Abstract][Full Text] [Related]
20. Glucocorticoid-induced hyperglycemia.
Kwon S; Hermayer KL; Hermayer K
Am J Med Sci; 2013 Apr; 345(4):274-277. PubMed ID: 23531958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
